Lung cancer

Read more about the patient satisfaction rates, our specialists' expertise, innovations, and wait times for lung cancer treatment.

Paul Baas
Because nearly all conceivable treatment options are available here, our multidisciplinary team can truly adapt the treatment to the condition.
Prof. dr. Paul Baas Pulmonologist

Patient satisfaction

Patient satisfaction rates are the opinions of our patients on the care and services they received at the Netherlands Cancer Institute. Our patients named expertise, personal care, information, trust, and the possibility to be involved as important aspects in their ratings of the Netherlands Cancer Institute.

8.8

Patiëntenwaardering

Patiënten met longkanker beoordelen het Antoni van Leeuwenhoek in 2022 met de volgende rapportcijfers.

Deel uw eigen ervaring
  • 9.1
    Deskundigheid
  • 9.0
    Uitleg
  • 9.0
    Luisteren
  • 8.8
    Wensen bij keuze behandeling
  • 8.7
    Samen beslissen
Op De Kelder
"In most hospitals, the condition will be central to the treatment, but here we also focus on psychosocial support."
Dhr. op de Kelder Patient

Expertise

Expertise is the experience and skill of our specialists, specific to this cancer type. We measure their expertise by keeping records of the numbers of patients treated, the numbers of patients requesting a second opinion, and the types of treatments being delivered.

The following data is based on the year 2020.

 

  • 4124

    patiënten met longkanker

Further division by treatment type

The expertise of our team of specialists is based on the three main treatments: the number of patients receiving surgery, radiation, and/or treatment with cancer drugs. We will give you further insights into our experience per treatment.

Surgical treatments (most common)

  • 154

    thoracale ingrepen
  • 19

    Ingrepen d.m.v. robotchirurgie

The Netherlands Cancer Institute is part of the quality registration audit “Dutch Lung Cancer Audit” which ensures an overview of the quality of care at this and other hospitals. The results are compared to the national average. 

Drug treatments (most common)

  • 357

    Chemotherapie
  • 330

    Doelgerichte therapie
  • 302

    Immuuntherapie

Many patients at the Netherlands Cancer Institute participate in a clinical trial looking into drug treatments, such as immunotherapy. These patients have not been included in the overview. 

Radiation treatments (most common)

  • 689

    radiotherapeutische behandelingen
  • 349

    stereotactische behandelingen
  • 265

    patiënten bestraald met een lang bestralingsschema
  • 84

    patiënten behandeld met een kort bestralingsschema
  • 5

    Samenwerkingspartners
Koen Hartemink in gesprek (longkanker)
Together with specialists across various disciplines, we prepare a personalized treatment plan for each patient.
Dr. Koen Hartemink Surgeon
This website uses cookies

We use cookies on our website to improve the user experience.